Lupin rises 1%; signs agreement with CSIR-National Chemical
Shares of Lupin added 1 percent intraday Thursday as company signed agreement with CSIR-National Chemical and DST for research on biosimilar therapeutic.
The company signed agreement with CSIR-National Chemical Laboratory and Department of Science and Technology for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic.
Dr Rustom Mody, Senior Vice President and Head-R&D, Biotechnology, Lupin said, "Biotech is one of Lupin's key growth drivers and we are committed to advancing our biotech R&D capabilities through strategic partnerships."
"Our collaboration with a premier institution like CSIR is an exemplary industry-academia collaboration that can further the development and commercialisation of biologics and biosimilars for a better and more affordable healthcare to customers across the globe," he added.
At 11:26 hrs Lupin was quoting at Rs 763.65, up Rs 3.05, or 0.40 percent.
It has touched a 52-week low of Rs 750.
Share price declined 47 percent in last 1 year.Posted by Rakesh Patil